1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
  • Home > Blog > Clinical Trial > Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma
Posted on Saturday, Mar 1, 2008

Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma

p>Clinical Trial Phase: Phase 2 Start Date: June 2005
Overall Status: Recruiting
Estimated Enrollment: 53

Rationale

Condition Keyword(s): Mesothelioma
Interventions:
Drug: pemetrexed
Drug: cisplatin

 

Phase II trial of Neoadjuvant Chemotherapy with Pemetrexed plus Cisplatin followed by Surgery and Radiotherapy in patients with Malignant Pleural Mesothelioma stage I-III.

The event-free survival is the primary endpoint for this study. This is a multicenter study and 53 Patients will be enrolled by June 2008.

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Outcome Measures for this Clinical Trial

Primary: Event-free survival baseline to objective progression, start of new therapy or death from any cause

Secondary

  • 1- and 2- year disease free survival baseline to post surgery
  • To determine complete pathological response rate surgical complete response post chemotherapy, surgery and radiation
  • Pharmacology toxicity every cycle
  • Time to objective tumor response baseline to response of tumor
  • Time to progressive disease baseline to measured progressive disease
  • Overall survival baseline to date of death from any cause

Inclusion Criteria

  • Histological proven diagnosis of stages I to III mesothelioma of the pleura.
  • Adequate organ function including the following: adequate bone marrow reserve, hepatic, renal, pulmonary and cardiac functions.
  • No prior systemic chemotherapy.
  • No previous surgical resection of mesothelioma, with the exception of previous chemical pleurodesis.
  • No previous radiation therapy.

Exclusion Criteria

  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Serious concomitant systemic disorders
  • Second active primary malignancy
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period
  • Inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone

Clinical Trials Locations, Contact Details, and Sponsors

Lead Sponsor: Eli Lilly and Company
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician.

Overall Clinical Trial Officials and Contacts
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon – Fri 9 AM – 5 PM Eastern time (UTC/GMT – 5 hours, EST) Study Chair Eli Lilly and Company

Overall Contact: They may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559

Additional Information

Information obtained from ClinicalTrials.gov on April 15, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00192010
Study ID Number: 8848
ClinicalTrials.gov Identifier: NCT00192010